0001178913-24-002391.txt : 20240802
0001178913-24-002391.hdr.sgml : 20240802
20240802163044
ACCESSION NUMBER: 0001178913-24-002391
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240731
FILED AS OF DATE: 20240802
DATE AS OF CHANGE: 20240802
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Toledano Miranda Jayne
CENTRAL INDEX KEY: 0001686530
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38556
FILM NUMBER: 241171511
MAIL ADDRESS:
STREET 1: C/O COMPASS THERAPEUTICS, INC.
STREET 2: 80 GUEST STREET, SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02135
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Entera Bio Ltd.
CENTRAL INDEX KEY: 0001638097
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: KIRYAT HADASSAH, MINRAV BUILDING
STREET 2: FIFTH FLOOR
CITY: JERUSALEM
STATE: L3
ZIP: 9112002
BUSINESS PHONE: 972-2-532-7151
MAIL ADDRESS:
STREET 1: KIRYAT HADASSAH, MINRAV BUILDING
STREET 2: FIFTH FLOOR
CITY: JERUSALEM
STATE: L3
ZIP: 9112002
4
1
zk2431765.xml
X0508
4
2024-07-31
0
0001638097
Entera Bio Ltd.
ENTX
0001686530
Toledano Miranda Jayne
KIRYAT HADASSAH,
MINRAV BUILDING, 5TH FLOOR
JERUSALEM
L3
9112002
ISRAEL
1
1
0
0
Chief Executive Officer
0
Ordinary Shares, par value NIS 0.0000769 per share
2024-07-31
4
A
0
124121
0.00
A
234873
D
Stock Option (Right to Buy)
1.99
2024-07-31
4
A
0
500000
0
A
2034-04-19
Ordinary Shares, par value NIS 0.0000769 per share
500000
500000
D
Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 19, 2024, subject to approval by the Company's shareholders, which was obtained on July 31, 2024. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 19, 2024.
This grant of options was approved by the Board on April 19, 2024, subject to approval by the Company's shareholders, which was obtained on July 31, 2024. The options vest over a three-year period that commenced on April 19, 2024, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.
/s/ Dana Yaacov-Garbeli, Attorney-in-Fact
2024-08-02